11 May 2023

Cellular Origins Partners With ScaleReady to Simplify, Standardize, and Automate Cell Therapy Manufacturing

Partnership aims to integrate ScaleReady’s CGT manufacturing workflow with Cellular Origins’ robotic technology
Initially focussed on automation of ScaleReady’s G-Rex platform

1 March 2023

Bio-Techne Announces Investment in Wilson Wolf

Bio-Techne Corporation announced Wilson Wolf Manufacturing has met the trailing 12-month earnings before interest, taxes, depreciation, and amortization (EBITDA) target...

26 April 2022

Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf

HOUSTON, April 26, 2022 (GLOBE NEWSWIRE) -- -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the...

14 December 2021

Bio-Techne Announces Future Wilson Wolf Purchase Agreement

Bio-Techne announced it has entered into a purchase option agreement with Wilson Wolf Corporation, solidifying resources and support for ScaleReady...

10 November 2021

ScaleReady Launches Second Generation of Wilson Wolf G-Rex Product

The second generation G-Rex500M-CS improves on the materials and ergonomics of the original G-Rex while retaining the same cell expansion...

3 November 2021

Bio-Techne Releases First GMP-grade Cytokines from New GMP Facility

ScaleReady sources Bio-Techne cytokines because of their commitment to supplying the entire cell and gene therapy industry with GMP-grade, animal...

2 June 2021

ScaleReady hosts ISCT Symposium on Intelligent Scale-up

ScaleReady recruited a prestigious panel of cell therapy manufacturing experts to discuss their experiences and strategies for commercial scale up...

6 January 2021

ScaleReady Launches

ScaleReady launches with the mission to make cell and gene therapy manufacturing practical and viable. Through a partnership between Bio-Techne,...

21 January 2020

Joint Venture formed by Bio-Techne, Fresenius Kabi, and Wilson Wolf

The joint venture focuses on providing scalable manufacturing technologies needed to develop and commercialize new cell and gene therapies. Each...